|
|
|
Pharmaceutical Manufacturing and Packing Sourcer |
|
|
|
|
|
 |
| |
|
|
|
|
Industry Insight
PMPS Industry Advisor Robert Harris discusses today's global supply chain logistics challenges in pharma, and how biologics have come to take a greater share in the pharmaceuticals market.
|
|
|
|
|
Pen and Auto-Injector Production
Springing to Life
Dr Tolga Goren of BAUMANN Springs investigates the growing role of springs in medical pens and auto-injectors. What are the development challenges that face a manufacturer of this small, yet essential, part of such an important device?
|
|
|
Parenteral Delivery Trends
Packaging Patient Needs
As demand for injection devices increases, so does the number of new solution providers in this field, states Rasmus Renstad at SHL Group. He shares his advice on how to find your perfect partner, and how to give patients exactly what they want.
|
|
|
|
|
Medical Device Identification
Labelled as Safe
The complexities of implementing the FDA’s unique device identifier system into medical device packaging can leave affected companies feeling daunted. Kevin Grygiel at PRISYM ID explains the advantages of label lifecycle management capability.
|
|
|
|
Counterfeits Update
Time for Action
Aegate’s Graham Smith reports on the Falsified Medicines Directive and the recently published Delegated Regulation, and considers how implementation will work in practice at each point in the pharma supply chain.
|
|
|
Serialisation Requirements
Mark My Words
What coding and marking options are available to manufacturers to help fight counterfeiters? Richard Nemesi at Videojet Technologies outlines a number of solutions that can enhance traceability, which in turn will protect product authenticity, consumer safety and brand reputation.
|
|
|
|
Cold Chain Management
Logistical Nightmare
Mark Sawicki at Cryoport advocates the use of controlled facilities, dry vapour packaging and tracking to take control of the transport of temperature-sensitive pharmaceuticals for clinical trials.
|
|
|
Pharma Air Freight
Better Together
Can pharma companies do more to enhance the supply chain? Pelican BioThermal’s Ira Smith believes that greater collaboration between shippers and 3PLs – and, ultimately, formation of a global regulatory standardisation – is key to success. |
|
|
Q&A: Industry Efficiency
Collaboration is King
Mark Blanchard at BioPhorum Operations Group describes to PMPS how stakeholders throughout the pharma supply chain can work together better – by sharing knowledge, rather than adapting an “us versus them” mentality. |
|
|
FlyPharma Event Preview
Pharma Takes Flight
Putting the spotlight on the benefits of collaboration between pharma shippers and logistics service providers, the FlyPharma Conference 2016 offers a great opportunity to network with like-minded industry decision-makers and gain insight into making the pharma supply chain stronger. |
|
|
|
Device Studies
Responsive Performance
It can be both difficult and expensive for researchers to manage medical device clinical trials. However, Grant Dietrich at Cenduit explains that with the right interactive response technology, it could be made cheaper and more efficient.
|
|
|
|
Supply Chain Operations
Waste Not, Want Not
Could Big Pharma’s resistance to change restrict manufacturers’ ability to apply a new, flexible approach to efficiency? Hugh Williams from Hughenden Consulting challenges the industry to be more open to an integrated, end-to-end supply chain.
|
|
|
Continuous Manufacturing
Keep it Moving
Peter Webster at PCI Pharma Services and Duncan Betteley at S3 Process Ltd offer their views on continuous manufacturing methods as an alternative to batch production – and warn that pharma’s hesitancy to consider this approach causes it to fall behind the levels of progression other industries are experiencing.
|
|
|
|
Safe Drug Storage
Kept in Check
Legislation protecting medical products against temperature increases during storage is strict, but necessary to ensure drug integrity. Air conditioning equipment has advanced considerably, but what do you do when things go wrong? Carl Webb at Andrews Sykes Specialist Hire reports.
|
|
|
|
|
End of the Line
Wait and See
Outlining the implications of a possible UK ‘Brexit’ from the EU for pharma, Robert Harris wonders what might happen to the relationship between the EMA and the MHRA, as well as other healthcare bodies.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
E Ink and Faubel Unveil the Med Label to Revolutionize the Clinical Trial Supply Chain
E Ink® Holdings, "E Ink" (8069.TW), the leading innovator of electronic
ink technology and Faubel & Co. Nachf. GmbH, a proven supplier to
the pharmaceutical and chemical industry, announced the availability of
the Faubel-Med® Label, a smart label for investigational medicinal
products. The Med Label features E Ink’s low-voltage film technology,
bringing display modules and new system designs to pharmaceutical
packaging.
More info >> |
|
 |
White Papers |
 |
|
Case Study: Cmed’s Mobile Data Management Solution
Cmed Clinical Services
The trial presented to Cmed was a randomized, double blinded, placebo
and active controlled study to evaluate the cardiac safety of multiple
doses of [study drug] in health volunteers.
The pharmaceutical
company, who were into the second year of development of a potential
blockbuster compound for the treatment of chronic myelogenous leukaemia
(CML), were requested by the FDA to design a trial to provide
information on the cardiac safety of different dose levels of the study
drug in healthy adult volunteers. The primary objective of the study was
specifically to find the maximum tolerated dose before QTc levels
became unsafe. All development of the compound was put on hold until the
results of this study were submitted to the FDA and approval granted
for the compound to progress into full development.
More info >> |
|
 |
Industry Events |
 |
On Helix 2018
10-11 July 2018, The Cambridge Building, Babraham Research Campus
ON Helix is a two-day event aimed at informing delegates
of how to turn early stage inventions and ideas into innovative health treatments
(new medicines, novel biomarkers, useful medical devices or improved medical
practices).
More info >> |
|
|
